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Abstract 
Much effort is currently being placed into developing new blood tests for cancer 
diagnosis in the hope of moving cancer diagnosis earlier and by less invasive means 
than current techniques, e.g., biopsy. Current methods are expected to diagnose and 
begin treatment of cancer within 62 days of patient presentation, though due to high 
volume and pressures within the NHS in the UK any technique that can reduce time to 
diagnosis would allow reduction in the time to treat for patients. The use of 
vibrational spectroscopy, notably infrared (IR) spectroscopy, has been under 
investigation for many years with varying success. This technique holds promise as is 
would combine a generally well accepted test (a blood test) with analysis that is 
reagent free and cheap to run. It has been demonstrated that, when asked simple 
clinical questions (i.e., cancer vs. no cancer), results from spectroscopic studies are 
promising. However, in order to become a clinically useful tool, it is important that 
the test differentiates a variety of cancer types from healthy patients. This study has 
analysed plasma samples with attenuated total reflection Fourier-transform IR 
spectroscopy (ATR-FTIR), to establish if the technique is able to distinguish normal 
from primary or metastatic brain tumours. We have shown that when asked specific 
questions, i.e., high-grade glioma vs. low-grade glioma, the results show a 
significantly high accuracy (100%). Crucially, when combined with meningiomas and 
metastatic lesions, the accuracy remains high (88-100%) with only minimal overlap 
between the two metastatic adenocarcinoma groups. Therefore in a clinical setting, 
this novel technique  demonstrates potential benefit when used in conjuction with 
existing diagnostic methods. 
 
 
Keywords: ATR-FTIR spectroscopy, biofluids, brain tumours, classification, 
sensitivity, specificity 
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Introduction 
Blood testing for cancer diagnostics is a popular ideal. It uses an acceptable patient 
test, i.e., a blood test, which is minimally-invasive and machine analysed, can be run 
on a mass scale, and can target specific markers circulating in the blood. Whilst some 
cancers can be identified by the use of biomarkers, there are currently no such 
markers for primary or metastatic brain tumours, nor are any biomarkers yet involved 
in a mass-screening programme [1]. Brain tumours, both primary and metastatic, 
often present with a range of non-specific symptoms. The diagnostic process involves 
a combination of history taking, examination and radiology to determine the presence 
of a tumour and its possible origin [2]. There are specific radiological appearances 
that can help differentiate between primary and metastatic brain tumours; however, 
these rules do not always hold true [3]. A brain tumour may also be the first 
presentation of a metastatic cancer from elsewhere within the body; this accounts for 
up to a quarter of brain tumours [4]. Currently, a combination of radiological imaging 
and histology is used to detect the primary origin of a brain tumour. When metastatic, 
pathologists can apply immunohistochemical stains to formalin-fixed paraffin-
embedded (FFPE) tissue, within which a combination of positive and negative stains 
can help determine a primary site of origin. 
Over recent years the potential of vibrational spectroscopy has been touted as 
an ‘inexpensive, high throughput and reagent-free’ cancer diagnostic tool. In vivo 
studies have shown great promise using both tissue and blood component analysis 
with detection of cancer vs. non-cancer in many pilot studies showing promising 
results [5,6]. When considering biofluids, predominantly serum has been analysed for 
brain cancer, using attenuated total reflection Fourier-transform infrared (ATR-FTIR) 
spectroscopy, with varying sample methods used [7]. This is due to the erythrocyte 
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component in whole blood providing a strong interfering spectroscopic signal, likely 
masking the underlying changes seen in cancer vs. non-cancer patients [8]. The main 
limitations of these studies focus around different methods of sample preparation and 
analysis. No universal method of spectral analysis has yet been agreed. Butler et al. 
attempted to outline suggested methods of applying and analysing spectroscopic 
techniques on a variety of tissues, though it is unclear how widely accepted this has 
been [9]. 
Some studies have also compared the use of plasma or serum, with similar 
results. FTIR or Raman spectroscopy methods with biofluids have been used with a 
wide range of cancers; from head and neck (75% classification accuracy), bladder 
cancer (up to 80% accuracy), ovarian and endometrial cancer (96% and 81% 
respectively) and brain tumours (93% high-grade, 96% low-grade) [8, 10-16]. 
Spectral differences between gastric cancer patients vs. normal controls, leukaemia vs. 
normal controls and lung cancer vs. normal controls have all been demonstrated by a 
Chinese group [17-21]. These studies all demonstrate different points within the 
spectra of normal vs. malignant that exhibit specific changes. Whilst sensitivities and 
specificities have been high within the majority of these studies, they have all asked 
specific questions of the data, e.g., cancer type vs. normal control, gliomas vs. 
meningioma. 
There is then the limit of what question does ATR-FTIR need to answer. 
Within clinical medicine detection of a specific cancer is beneficial if suspected based 
on clinical suspicion. However, more frequently as symptoms are vague, a tool would 
be required to detect one from a number of primary cancers to provide early 
diagnostic utility. However, the majority of laboratory studies have focused on one 
cancer type and detecting its presence. It has been proposed that spectroscopy, more 
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 5 
specifically, FTIR spectroscopy, could be used as a stand-alone tool for diagnostics or 
within screening [20]. However, when either a healthy person (i.e., one without 
knowingly having the disease being tested for) presents for screening, or an unhealthy 
patient (i.e., a person with a collection of symptoms not specifically demonstrating a 
defined underlying illness) with a non-specific history presents, the ability of a 
spectroscopic blood test to detect a cancer and its tissue origin from a range of options 
remains to be tested. Studies demonstrating detection of low-grade malignancies are 
also lacking; within brain tumours, the differentiation of low- and high-grade gliomas 
has been demonstrated to good effect [14]. Hands et al., have also compared primary 
to metastatic tumours; however, this classed all brain tumours together vs. all types of 
metastasis [14]. On tissue, Krafft et al. have attempted to differentiate primary site 
from metastasis with limited effect. This study demonstrated that it was possible to 
separate by tumour type; however, adenocarcinomas for example, from two different 
primary sites gave markedly similar results [21]. Therefore in order to be clinically 
effective and aid other current diagnostic tools by adding value (i.e., providing 
information by less invasive means or more quickly than current testing), any new test 
must be able to detect cancer, with high accuracy, and aim to localise the cancer from 
a range of primary sites, as is currently possible following biopsy with the use of 
immunohistochemistry. 
The changes found within ATR-FTIR studies of peripheral blood components 
between cancer and non-cancer states are not yet clearly understood. Changes are 
seen at several wavelengths, e.g., Apolipoprotein A1 within endometrial cancer [15] 
and several reports of changes in vibrations from C-O, C=O and C-H bonds 
associated with lipids and proteins within patients with brain metastases [14]. It has 
also been shown to be possible to detect epidermal growth factor receptor (EGFR) 
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mutation status from peripheral blood of lung cancer patients [22]. This may be due to 
circulating tumour cells within the blood or in the case of ATR-FTIR spectroscopy-
detected protein changes within the peripheral blood.  These changes are likely caused 
by the release of enzymes and cytokines from the tumour as it grows. 
Worldwide, neurological disorders account for >20% of disease burden and 
are frequently seen in General Practitioner (GP) clinics [23]. If a typical secondary 
care neurology clinic is used as an example, patients are referred via their GP due to 
underlying symptoms such as headaches. From the history, examination and any 
relevant investigations the clinician determines the underlying cause. MacDonald et 
al. looked at an unselected population from GP services in London who had been 
referred to tertiary neurology services. This was to understand the range of underlying 
diagnoses. They found non-tumour related pathology made up the vast majority of 
these presentations [24]. Similar results have been reported elsewhere, including a 
Nigerian study [23]. Hence any new investigative tool would need a high accuracy in 
picking out individual patients with a brain tumour against a backdrop of many 
confounding factors. 
Therefore this study was performed to determine the accuracy of ATR-FTIR 
spectroscopy in detecting biochemical signatures of a range of primary and metastatic 
brain tumours from blood plasma when analysed in the same grouping. This approach 
aims to investigate whether ATR-FTIR spectroscopy is a useful tool to detect tumours 
within blood plasma when asked to differentiate on a wider-scale more akin to a 
typical clinical setting. Tumours were selected to encompass primary brain tumours 
and metastasis that commonly occur within the brain. Lung adenocarcinoma and 
malignant melanoma cause brain metastasis frequently, with lung adenocarcinoma 
resulting in the majority of brain metastasis [25-27]. Colorectal adenocarcinoma was 
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 7 
chosen to compare two adenocarcinomas with often similar morphology but slightly 
different immunohistochemical profiles to determine if ATR-FTIR spectroscopy 
would be able to differentiate two adenocarcinomas of different primary origins. To 
the authors’ knowledge this is the first paper to compare multiple tumour types using 
ATR-FTIR spectroscopy on plasma. 
Methods 
Plasma from 50 patients comprising normal, i.e., no known brain tumour (n=10), 
glioma high-grade (n=5) or low-grade (n=5), meningioma (n=10) and brain metastasis 
patients, a mix of lung adenocarcinoma (n=7), colorectal adenocarcinoma (n=7) and 
malignant melanoma (n=6) patients were obtained from the Brain Tumour North 
West tissue bank (BTNW). This was under ethical approval number (RTB - ethics 
NRES14/EE/1270). These were stored at -80°C and defrosted prior to use. From the 
samples, 50 μL of plasma was pipetted onto a glass slide wrapped in aluminium foil. 
This has previously been shown to be as effective as slides such as CaF2-coated 
windows [28]. 
The slides were left to dry overnight prior to spectral acquisition. ATR-FTIR 
spectra were collected using a Bruker TENSOR 27 FTIR spectrometer with Helios 
ATR attachment containing a diamond crystal internal reflective element and a 45o 
incidence angle of IR beam. In the ATR module, the light goes through the sample in 
a reflectance mode and, after successive reflections between the sample and the ATR 
crystal, an evanescent wave is generated contained the attenuated IR signal of the 
sample [29-30]. For each case 32 scans with 8 cm-1 spectral resolution were taken at 
10 randomly selected points. A new background spectrum was collected prior to each 
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new sample, followed by cleaning of the crystal with distilled water. The sampling 
aperture was 250 μm × 250 μm and the mirror velocity was 2.2 Hz. 
Computational analysis was then performed within a Matlab environment 
using IRootlab toolkit as a user interface [31]. Spectra were then pre-processed by 
cropping the region of interest (1850-800 cm-1), followed by polynomial baseline 
correction and vector normalisation. Following this, principal component analysis-
linear discriminant analysis (PCA-LDA) was performed to determine differences 
between the groups, along with PCA-linear discriminant classifier (PCA-LDC) to 
calculate the classification accuracy of each group. In addition, support vector 
machines (SVM) was employed for class differentiation using a radial basis function 
kernel. All PCA-LDC and SVM parameters (gamma value and number of support 
vectors) were optimized using leave-one-out cross-validation. Sub-dataset generation 
specification algorithm was employed for assigning 10% of the samples as external 
test dataset. The number of principal components was determined according to the 
maximum explained variance and lowest root mean square error of cross-validation. 
Statistical significance was then determined using a one-way ANOVA within PRISM 
(GraphPad Software) statistical analysis software. 
Results 
From the 50 cases 500 spectra (i.e., 10 spectra per sample) were obtained. Following 
pre-processing (see Figure 1 for mean spectra), a PCA-LDA was performed to 
identify if the groups (or categories) are significantly different based upon their 
spectra, along with PCA-LDC to generate confusion matrices to look at the accuracy 
of the spectra in detecting each tumour type. Spectra appeared visibly different within 
the 1100-1000 cm-1 range. 
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Analysis was then performed initially looking at normal vs. each tumour group and 
then combining all groups together to determine if they could be differentiated 
accurately from each other, as would occur in a typical clinical setting. 
 
Figure 1. A) Mean pre-processed spectra with standard-deviation for all groups 
analysed; B) mean pre-processed spectra for all groups analysed with tentative 
assignment of main bands [29, 32]. Key: N, normal; LG, low-grade; HG, high-grade; 
Men, meningioma; MM, melanoma metastasis; CA, colorectal adenocarcinoma 
metastasis; LA, lung adenocarcinoma metastasis. Band assignment: νs, symmetric 
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 10 
stretching; νas, asymmetric stretching; δ, deformation; blue: DNA/RNA absorptions; 
red: protein absorptions; green: lipids absorptions. 
Figure 2 shows normal compared to low-grade and high-grade gliomas. It 
shows how well the spectra are separated based upon them being classed as normal or 
high-grade, particularly with SVM, with a100% accuracy (Table 1). 
 
Figure 2. Discriminant function (DF) plot for PCA-LDC (A) and SVM (B) models. N 
stands for normal, LG for low-grade glioma, and HG for high-grade glioma samples. 
PCA-LDC performed with 10 principal components and SVM performed using 48 
support vectors. 
 
Table 1. Confusion table containing the accuracy for PCA-LDC and SVM models for 
distinguishing control (N), low-grade (LG) and high-grade (HG) gliomas.  
 
PCA-LDC 
(accuracy = 90%) 
SVM 
(accuracy = 100%) 
 N LG HG N LG HG 
N 89% 11% 0% 100% 0% 0% 
LG 16% 84% 0% 0% 100% 0% 
HG 0% 2% 98% 0% 0% 100% 
 
This differentiation between the three groups is statistically significant using a one-
way ANOVA, as shown in Table S1 [see Supplementary Information (SI)]. Using the 
A) B)
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SVM method as the primary example, similar results are seen throughout, with 
minimal overlap seen within the two metastatic adenocarcinoma groups (Figures 3-6 
and Tables 2-4). Given the morphological and immunohistochemical similarities 
between these two tumours this is to be expected. The PCA-LDC results, demonstrate 
high accuracy, which drops as the clinical question becomes increasingly complex 
(i.e., by adding in different tumour types). 
 
A)
C)
E)
B)
D)
F)
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Figure 3 Discriminant function (DF) plot for PCA-LDC and SVM models. (A) PCA-
LDA and (B) SVM for normal (N) vs. meningioma (Men); (C) PCA-LDA and (D) 
SVM for normal (N) vs. metastasis (Met); (E) PCA-LDA and (F) SVM for normal 
(N) vs. different metastatic groups, colorectal adenocarcinoma (CA), lung 
adenocarcinoma (LA) and melanoma (MM). PCA-LDC performed with 10 principal 
components in (A)-(F), and SVM performed using 31 (A), 29 (D) and 140 (F)  
support vectors. 
 
Table 2. Confusion table containing the accuracy for PCA-LDC and SVM models for 
distinguishing control (N), meningioma (Men), metastasis (Met), colorectal 
adenocarcinoma (CA), lung adenocarcinoma (LA), and melanoma (MM). 
 PCA-LDC 
(accuracy = 87%) 
SVM 
(accuracy = 95%) 
 PCA-LDC 
(accuracy = 94%) 
SVM 
(accuracy = 100%) 
 N Men N Men  N Met N Met 
N 89% 11% 91% 9% N 96% 4% 100% 0% 
Men 14% 86% 0% 100% Met 8% 92% 0% 100% 
 PCA-LDC 
(accuracy = 63%) 
 SVM 
(accuracy = 97%) 
 N CA LA MM  N CA LA MM 
N 98% 1% 1% 0%  100% 0% 0% 0% 
CA 19% 38% 22% 21%  0% 88% 12% 0% 
LA 0% 16% 63% 21%  0% 0% 100% 0% 
MM 3% 28% 15% 54%  0% 0% 0% 100% 
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Figure 4 Discriminant function (DF) plot for (A) PCA-LDC and (B) SVM models. N 
stands for normal, LG for low-grade glioma, HG for high-grade glioma, Men for 
meningioma, and Met for metastasis samples. PCA-LDC performed with 10 principal 
components and SVM performed using 245 support vectors. 
 
Table 3. Confusion table containing the accuracy for PCA-LDC and SVM models for 
distinguishing normal (N), low-grade glioma (LG), high-grade glioma (HG), 
meningioma (Men), and metastasis (Met).  
 PCA-LDC 
(accuracy = 65%) 
SVM 
(accuracy = 97%) 
 N HG LG Men Met N HG LG Men Met 
N 75% 0% 8% 10% 7% 91% 0% 0% 9% 0% 
HG 10% 90% 0% 0% 0% 0% 100% 0% 0% 0% 
LG 30% 1% 41% 10% 18% 0% 0% 100% 0% 0% 
Men 4% 0% 3% 63% 30% 0% 0% 0% 100% 0% 
Met 4% 0% 15% 23% 58% 0% 0% 5% 0% 95% 
 
 
When examining the PCA-LDC, the classification accuracy drops further if the 
metastasis category is split by primary tumour location, with only the detection of 
high-grade glioma maintaining >90% (Figure 6). However, the use of SVM maintains 
A) B)
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accuracy approaching 100% for almost all groups. The overlap between meningioma 
and normal is difficult to explain without including patient factors within the 
algorithm, which is beyond the scope of this paper (Figure 6, Table 4). 
 
 
Figure 5 Discriminant function (DF) plot for (A) PCA-LDC and (B) SVM models. N 
stands for normal, LG for low-grade glioma, HG for high-grade glioma, Men for 
meningioma, MM for melanoma metastasis, CA for colorectal adenocarcinoma 
metastasis, and LA for lung adenocarcinoma metastasis.  PCA-LDC performed with 
10 principal components and SVM performed using 293 support vectors. 
 
 
 
 
 
 
 
 
 
 
 
 
A) B)
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Table 4. Confusion table containing the accuracy for PCA-LDC and SVM models for 
distinguishing control (N), low-grade glioma (LG), high-grade glioma (HG), 
meningioma (Men), and melanoma metastasis (MM), colorectal adenocarcinoma 
metastasis (CA), and lung adenocarcinoma metastasis (LA). 
 PCA-LDC 
(accuracy = 54%) 
SVM 
(accuracy = 97%) 
 N LG HG Men MM CA LA N LG HG Men MM CA LA 
N 85% 6% 0% 0% 9% 0% 0% 91% 0% 0% 9% 0% 0% 0% 
LG 25% 61% 4% 0% 10% 0% 0% 0% 100% 0% 0% 0% 0% 0% 
HG 8% 0% 92% 0% 0% 0% 0% 0% 0% 100% 0% 0% 0% 0% 
Men 4% 0% 0% 43% 36% 3% 14% 0% 0% 0% 100% 0% 0% 0% 
MM 0% 0% 0% 35% 22% 13% 30% 0% 0% 0% 0% 100% 0% 0% 
CA 0% 3% 0% 5% 28% 50% 14% 0% 0% 0% 0% 0% 88% 12% 
LA 18% 2% 0% 13% 29% 14% 24% 0% 0% 0% 0% 0% 0% 100% 
 
 Receiver operating characteristic (ROC) curves agree with the results in 
Tables 1-4, as can been seen in supplementary information Figures S2-S7 (see SI). 
Discussion 
With an ageing population, complex clinical presentations of cancer are 
becoming more frequent, with up to a quarter of all new brain tumour diagnoses 
representing metastases [4]. Therefore, this study was designed to mimic a clinical 
setting with a variety of primary and metastatic brain tumours. The aim was to 
determine if ATR-FTIR spectroscopy would be able to detect a brain tumour from 
peripheral blood and if so determine type. If this were to prove possible, the potential 
of ATR-FTIR in a frontline clinical setting as part of an initial workup of the patient 
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may be demonstrable, as has previously been proposed [20]. The metastatic brain 
tumours were chosen based on both propensity for cranial spread and to provide 
tumours, which are morphologically similar (lung and colorectal adenocarcinomas) 
and a contrast (metastatic melanoma) to enable testing of ATR-FTIR spectroscopy to 
differentiate metastatic tumours by their primary origin [25-27]. Our results 
demonstrate that ATR-FTIR spectroscopy is able to detect patients with primary or 
metastatic brain tumours using plasma samples from peripheral blood. The SVM 
method of analysis, has demonstrated accuracy from 88-100% with minimal overlap 
between the two metastatic adenocarcinoma groups primarily, with ROC curves 
demonstrating specificity and p <0.001. Given the similar morphological features of 
the two adenocarcinoma groups this was expected. Accuracy decreases slightly as the 
clinical question progresses from cancer vs. no cancer to which type of brain tumour 
and then primary metastatic location. With the differences seen within the spectra 
(Figure 1), this when combined with the classification accuracy, demonstrates the 
potential of ATR-FTIR spectroscopy to be built into clinical practise as a primary 
diagnostic step. 
Previous studies performed by both this group and others have demonstrated 
that spectroscopic techniques can differentiate normal from cancer cases within 
biofluids alone. Owens et al. found a 93% accuracy when determining ovarian cancer 
patients from negative cases using plasma alone [11]. Gajjar et al. demonstrated 
similar findings when also comparing normal to ovarian and endometrial cancer 
patients [5]. Moving to bladder cancer, Ollesch et al. were also able to separate 
normal from bladder cancer patients [8]. Within brain tumours, Hands et al. have also 
shown the capabilities of ATR-FTIR spectroscopy with plasma, demonstrating 
classification of high and low grade glial tumours with accuracies of over 90%. These 
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dip slightly when comparing to metastatic tumours [13-14]. Therefore our results, 
demonstrate comparable accuracies when compared across the published literature. 
They also take forward most of the studies above by combining different tumour 
types, both primary and metastatic. 
Our study, has however, not included confounding patient factors within the 
analysis.  The number or location of the brain tumours is unknown, nor with the 
metastatic patients the burden of metastatic disease. When patients initially present to 
a medical professional, it is unlikely they will have had all investigations completed 
and a known diagnosis, therefore for this initial study, it was felt to add other 
confounding factors into the algorithm would prove too complex and unlikely to yield 
usable results. Brain tumours account for a small number of diagnosed tumours per 
annum (11,432/359,960 in 2015) in comparison to extracranial tumours therefore it 
was felt limiting this study by size and location of brain tumours would be unlikely to 
be of benefit [33, 34]. 
To take this technique further forward and validate the results seen above 
clinically, it would be crucial to test a wide range of non-cancer disorders to ensure 
this would not affect the results. Current clinical trials for use of ATR-FTIR 
spectroscopy currently underway should be able to determine if within a clinical 
setting this technique can maintain the accuracies seen within this study. It would also 
be interesting to test cancer patients without brain metastases to see if this impacted 
the results and how this could be differentiated. 
This study has shown that ATR-FTIR spectroscopy could play a role in 
plasma testing for both primary and extrinsic brain tumours. The advantages of ATR-
FTIR spectroscopy in a clinical setting would be the relative low-cost of 
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instrumentation; the fact that the technique is non-analyst dependent, thus not biased 
according to the analyst training; non-destructive, thus the sample could be reused for 
further analysis; and easily translated to automation, by using computer-based 
technologies. In addition, the use of ATR-FTIR spectroscopy clinically may be able 
to speed up the diagnostic process, though robust clinical studies would be required to 
eliminate any of the current diagnostic steps within the patient pathway. 
As limitation, for such chemometric methods and instrumental techniques to 
be translated into a clinical setting, all possible experimental and computation 
configurations should be analysed, where all possible circumstances must be taken 
into consideration before clinical implementation. Evaluation of further biochemical 
factors and test with larger datasets are necessary before translation. This paper shows 
the potential usefulness of ATR-FTIR allied with chemometric methods as a biofluid 
screening tool, which remains to be further investigated. 
Conclusions 
This study demonstrates that ATR-FTIR spectroscopy is able to differentiate brain 
tumour types from blood plasma with accuracies of up to 100%. Further work is 
required to determine if this technique can discrimianat tumours from complex non 
cancer related disorders in order to all clinical medicine to harness the use of ATR-
FTIR spectroscopy within the clincal pathway, hopefully decreasing time taken from 
clinical presentation to diagnosis. 
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Highlights 
 
 Vibrational spectroscopy can diagnose brain tumours in biofluids 
 Reagent-free and inexpensive blood test 
 Can be applied in a clinical setting with multiple tumour types 
 Accuracy in terms of sensitivity / specificity remains high 
 ATR-FTIR spectroscopy could be a robust diagnostic technique 
ACCEPTED MANUSCRIPT
